Jordan Dourlain

Ms. Jordan Dourlain

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
OBOmar Bushara
Omar Bushara
DDDavid Nicholas DeVaro
David Nicholas DeVaro
SAShawn S. Ahn
Shawn S. Ahn
JDJordan Dourlain
Jordan Dourlain
MFMohammad S. Farooq
Mohammad S. Farooq
SSSunil Singhal
Sunil Singhal
Introduction: SETD2 is an understudied gene that encodes for a histone methyltransferase implicated in lung cancer tumorigenesis and is found in up to 10% of all non-small cell lung cancer. With the largest cohort to date, we aim to elucidate the clinicopathologic characteristics and prognosis of SETD2-mutated lung adenocarcinoma. Methods: We obtained molecular genetics reports of lung cancer seen between 1 January 2015 and 4 January 2024. We identified all SETD2-mutated cancer and identified 500 consecutive cases prior to 4 January 2020 as a control group. Non-recurrent adenocarcinomas were included. Patient and tumor characteristics and recurrence-free survival (RFS) were compared. Fisher’s exact, Wilcoxon rank sum, and log-rank tests were used when appropriate. Kaplan–Meier plots and Cox proportional hazards models were used to analyze recurrence-free survival. Results: A total of 67 SETD2-mutated lung and 174 non-SETD2-mutated lung adenocarcinomas met inclusion criteria. SETD2-mutated tumors presented at earlier stages (55.2% vs. 17.8% stage I, 11.9% vs. 48.3% stage IV, p < 0.001). SETD2-mutated adenocarcinoma had a higher number of genetic mutations (median: 11 IQR: [8–15] vs. 7 [5–10], p < 0.001). In a univariable Cox analysis, SETD2 mutation was associated with improved RFS (HR 0.53 95% CI: [0.33–0.85], p = 0.008). In a covariate-adjusted model, SETD2 mutation trended towards improved RFS (0.71 [0.43–1.18], p = 0.10). Conclusions: These data suggest SETD2-mutated lung adenocarcinoma presents at significantly earlier stages, has a unique molecular profile compared to non-mutated tumors, and trends towards improved RFS in early-stage tumors. Future study is warranted on both patient outcomes and immunopathologic characteristics of SETD2-mutated lung adenocarcinoma.

3 July 2026 in JTCVS Open
Verified
Journal Article
Open access
JDJordan Dourlain
Jordan Dourlain
OBOmar Bushara
Omar Bushara
MFMohammad Saad Farooq
Mohammad Saad Farooq
JGJulia Gasior
Julia Gasior
KBKarina Bruestle
Karina Bruestle
SSSunil Singhal
Sunil Singhal